The aim of this study was to evaluate efficacy of (AZA) and (CYC) as a therapeutic regimen for interstitial lung disease associated with (SSc) and the results indicated that AZA can be effective in ameliorating or stabilizing lung function in selected SSc patient groups. PubMed, Rheumatol Int. 2014 May 7. (Also see: Pulmonary Fibrosis and Immunosuppressants)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.